STOCK TITAN
  1. Home
  2. News
  3. HEPA

Hepion Pharmaceuticals Inc - HEPA STOCK NEWS

Welcome to our dedicated news page for Hepion Pharmaceuticals (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hepion Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hepion Pharmaceuticals's position in the market.

News
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
Rhea-AI Summary
Hepion Pharmaceuticals has initiated wind-down activities in its Phase 2b ASCEND-NASH Trial due to resource constraints. The trial, evaluating the safety and efficacy of rencofilstat for NASH treatment, had 151 subjects randomized with 80 completing their Day 365 visits. The company plans to explore strategic alternatives following this decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
Rhea-AI Summary
Hepion Pharmaceuticals, Inc. (HEPA) appointed Michael Purcell to its Board of Directors, bringing over 37 years of experience in financial advisory services. Purcell's background includes roles at Deloitte & Touche LLP and positions on various company boards. His expertise enhances Hepion's strategic guidance and governance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.92%
Tags
management
-
News
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
Rhea-AI Summary
Hepion Pharmaceuticals, Inc. (HEPA) announces the immediate exercise of an outstanding Series B common stock purchase warrant by an institutional investor, resulting in gross proceeds of approximately $2.0 million. The investor will purchase 980,393 shares of Hepion common stock at a revised exercise price of $2.10 per share. Hepion will issue two new unregistered warrants to the investor, each allowing the purchase of 735,295 shares at an exercise price of $1.91 per share. The transaction is expected to close by February 21, 2024, with net proceeds intended for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
none
News
Hepion Pharmaceuticals to Present at NASH-TAG 2024
Rhea-AI Summary
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced the presentation of an abstract highlighting its lead drug candidate, rencofilstat, at the 2024 NASH-TAG Conference. The abstract showcases hepatic functional improvement detected by HepQuant DuO within 120 days of treatment with rencofilstat in NASH subjects with ≥F3 fibrosis. The presentation will be held on Saturday, January 6, 2024, and the materials will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
conferences
-
News
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
Rhea-AI Summary
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced a strategic restructuring plan to preserve capital, reduce operating costs, and explore strategic and financing alternatives. The company's cash runway has been extended into Q2 2025. The CEO has resigned, and the CFO has been appointed as interim CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
management
-
News
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
Rhea-AI Summary
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) to present at the 7th Obesity & NASH Drug Development Summit on the use of AI/ML and Multi-Omics for Clinical NASH Study Enrichment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
conferences
News
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
Rhea-AI Summary
Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) announced additional efficacy data for rencofilstat, its lead drug candidate. Results from ALTITUDE-NASH trial showed significant reduction in liver stiffness and improvement in liver health indicators, confirming rencofilstat's effectiveness in treating severe liver disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.34%
Tags
clinical trial
-
News
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Rhea-AI Summary
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces the release of additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, following a late-breaker poster presentation at AASLD The Liver Meeting® 2023. The data will be released after market close on November 13, 2023, and will be discussed in a conference call at 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
clinical trial
-
News
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
Rhea-AI Summary
Hepion Pharmaceuticals announces positive results from a research study showing that their lead drug candidate, rencofilstat, significantly suppressed tumor growth in mice infected with the hepatitis C virus. The drug demonstrated preventative and regressive anti-tumor activity, outperforming other anti-HCV agents such as sofosbuvir and velpatasvir. Rencofilstat's pleiotropic effects make it a promising treatment for liver cancer arising from HCV infection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
News
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
Rhea-AI Summary
Hepion Pharmaceuticals enters into securities purchase agreement for the sale of 980,393 shares of common stock at $5.10 per share in a registered direct offering. The gross proceeds are expected to be approximately $5.0 million. The net proceeds will be used for clinical development and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
offering
Stock HEPA logo
Hepion Pharmaceuticals Inc

Nasdaq:HEPA

HEPA Rankings

#5332 Ranked by Market Cap
#4815 Ranked by Stock Gains
N/A Ranked by Dividends

HEPA Stock Data

9.50M
3.86M
0.39%
17.23%
1.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Edison

About HEPA

hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.